In Immune Checkpoint Blockade (ICPB)-treated mice, anti-CTLA-4+ anti-OX40-based treatments induce powerful and durable responses in orthotopic and subcutaneous mesothelioma tumor model. This evidence concerns the gene CTLA4 and neoplasm.